Semperit (SEM) Q2 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2025 earnings summary
23 Nov, 2025Executive summary
Revenue declined 7.2% year-over-year to EUR 320.5 million in H1 2025, with EBITDA down 35.2% to EUR 30.7 million and earnings after tax negative at EUR -11.2 million.
Q2 2025 saw a significant EBITDA improvement to EUR 19.6 million, up 77% quarter-on-quarter, but not enough to offset a weak Q1.
Order intake and backlog improved from March onward, exceeding last year's levels, supported by Q2 recovery.
Strong balance sheet maintained with equity ratio at 45.5%–46% and cash reserves of EUR 112.9–113 million.
Market uncertainty, especially from US tariffs and project delays, delayed customer investments.
Financial highlights
H1 2025 EBITDA margin was 9.6% (down 4.1pp), EBIT margin 0.8% (down 6.0pp), and EPS at EUR -0.54.
Free cash flow was EUR 13.9 million; CapEx reduced by over 50% to EUR 18.5 million.
Net financial debt increased to EUR 118.6 million; leverage ratio at 1.7x EBITDA.
Dividend of EUR 0.50 per share (EUR 10.3 million) paid in April 2025.
EBIT dropped 88.8% to EUR 2.6 million; return on equity at -5.6%.
Outlook and guidance
Operating EBITDA for 2025 is guided at EUR 65–85 million, with EUR 5 million in digitalization project costs.
CapEx for 2025 expected at EUR 50 million, with flexibility to adjust to market conditions.
Recovery expected in H2 2025, but high uncertainty remains due to US tariffs and market conditions.
Medium-term drivers include EU infrastructure programs and rising defense expenditures.
Actively screening for inorganic growth and acquisition opportunities.
Latest events from Semperit
- Operating EBITDA beat guidance and margin rebounded; 2026 targets growth and higher profitability.SEM
Q4 202518 Mar 2026 - EBITDA up 7.9% to €47.3m, medical business divested, and cost savings exceeded targets.SEM
Q2 20241 Feb 2026 - EBITDA up 11.9% to EUR 63.9m, profit positive, and 2024 guidance reaffirmed.SEM
Q3 202416 Jan 2026 - EBITDA up 21%, earnings positive, and free cash flow nearly doubled despite weak demand.SEM
Q4 202424 Dec 2025 - Q3 2025 profit turnaround and strong order intake support a confident full-year EBITDA outlook.SEM
Q3 202517 Dec 2025 - Q1 2025 saw steep profit declines, improved cash flow, and cautious optimism for H2 recovery.SEM
Q1 202526 Nov 2025